TECHLAB® Inc., a leader in infectious disease diagnostics, today announced it has partnered with the New River Valley COVID-19 Task Force to cost-effectively expand future COVID-19 testing capacity. Under this agreement, the New River Health District secures access to TECHLAB’s analyte-specific reagents (ASRs) for SARS-CoV-2 for as little as $7-9 per use.
“As a company founded and headquartered here in the New River Valley, we are proud to work closely with public health officials to provide a cost-effective and flexible option to increase their COVID-19 testing,” said Joel Herbein, Ph.D., Vice President of Scientific Affairs at TECHLAB. “Our analyte-specific reagents can be used now to maximize COVID-19 testing by any lab that is CLIA-certified to perform medium- and high-complexity testing. We are also incorporating our ASRs into 96-well and rapid antigen tests and plan to submit to the U.S. FDA for emergency use authorization.”
The founders of TECHLAB® met in the late 1970s at Virginia Tech’s Anaerobe Laboratory, where they were investigating diagnosis and treatments for Clostridium difficile infection. Led by Dr. Tracy Wilkins, the researchers developed the first commercial diagnostic reagents for C. difficile disease.
Demand for the antiserum grew quickly when it was discovered that C. difficile is a major hospital pathogen, and TECHLAB was incorporated in 1989 to produce and distribute the product.TECHLAB® designs, develops, and manufactures enteric diagnostics that are distributed worldwide. We have ISO 13485 certification and MDSAP, and FDA registration.
TECHLAB designs, develops, and manufactures diagnostics in the USA. We have ISO 13485 MDSAP certification and our products are commercially available for clinical use worldwide.
2001 Kraft Drive
Blacksburg, VA 24060